1. Department of Pharmacy, Clínica Universidad de Navarra, AV/Pio XII, 36, 31.008, Pamplona, Navarra, Spain 2. Department of Ophthalmology, Clínica Universidad de Navarra, AV/Pio XII, 36, 31.008, Pamplona, Navarra, Spain
Abstract:
Objective
To assess the cost-effectiveness of ranibizumab compared with pegaptanib in the treatment of patients with minimally classic/occult neovascular age-related macular degeneration (AMD), from a societal perspective in Spain.